{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:51:03Z","timestamp":1785484263325,"version":"3.56.0"},"reference-count":35,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2019,6,29]]},"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>Treatment of rheumatoid arthritis (RA) has improved substantially during the last decades, mainly due to the development and introduction in everyday practice of new, highly efficacious, disease-modifying antirheumatic drugs (DMARDs), more optimal usage of them, earlier diagnosis and tighter control of disease activity targeting at remission. Methotrexate is still today the anchor drug and the first-line treatment after diagnosis. However, numerous studies comparing methotrexate and biologic DMARDs, as well as new targeted synthetic DMARDs, both in early as in more established disease, have shown consistently better efficacy of the latter compared with methotrexate, with methotrexate yielding remission to maximum half of patients. This could suggest a new paradigm shift with earlier start of a biologic or a targeted synthetic DMARD, with the possibility of subsequent discontinuation in case of achievement of stable remission. Several strategy trials, however, have shown that there might be a clinical and structural benefit of initial, aggressive therapy, possibly even associated with higher chance of remaining in remission, after cessation of the biologic DMARD and continuing with methotrexate alone, but they have failed to show a clear advantage of such an aggressive treatment strategy. This might become a valuable option for the future treatment algorithm of RA, especially for a subgroup of patients with RA, but further confirmation from future research is needed. The crucial role of glucocorticoid use as part of the combination strategy should be acknowledged, and strategy trials should include this combination as an active comparator.<\/jats:p>","DOI":"10.1136\/rmdopen-2019-000993","type":"journal-article","created":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T11:45:32Z","timestamp":1564227932000},"page":"e000993","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":48,"title":["Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift"],"prefix":"10.1136","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2669-1247","authenticated-orcid":false,"given":"Katerina","family":"Chatzidionysiou","sequence":"first","affiliation":[{"name":"First Department of Propaedeutic and Internal Medicine and Joined Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros P","family":"Sfikakis","sequence":"additional","affiliation":[{"name":"First Department of Propaedeutic and Internal Medicine and Joined Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,7,27]]},"reference":[{"key":"2025090312552001000_5.2.e000993.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.109983"},{"key":"2025090312552001000_5.2.e000993.2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-8-199604150-00001"},{"key":"2025090312552001000_5.2.e000993.3","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"The Lancet"},{"key":"2025090312552001000_5.2.e000993.4","first-page":"585","article-title":"Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease","volume":"16","author":"Fuchs","year":"1989","journal-title":"J Rheumatol"},{"issue":"5 Suppl 31","key":"2025090312552001000_5.2.e000993.5","first-page":"S158","article-title":"Disease-Modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis","volume":"21","author":"Mullan","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312552001000_5.2.e000993.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.11.1211"},{"key":"2025090312552001000_5.2.e000993.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203130"},{"key":"2025090312552001000_5.2.e000993.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461"},{"key":"2025090312552001000_5.2.e000993.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210602"},{"key":"2025090312552001000_5.2.e000993.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151902"},{"key":"2025090312552001000_5.2.e000993.11","doi-asserted-by":"crossref","unstructured":"Radner H , Smolen JS , Aletaha D . Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther 2014;16.doi:10.1186\/ar4491","DOI":"10.1186\/ar4491"},{"key":"2025090312552001000_5.2.e000993.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.141523"},{"key":"2025090312552001000_5.2.e000993.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201247"},{"key":"2025090312552001000_5.2.e000993.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"2025090312552001000_5.2.e000993.15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0140-6736(16)30363-4","article-title":"Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial","volume":"388","author":"Bijlsma","year":"2016","journal-title":"The Lancet"},{"key":"2025090312552001000_5.2.e000993.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.21519"},{"key":"2025090312552001000_5.2.e000993.17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (comet): a randomised, double-blind, parallel treatment trial","volume":"372","author":"Emery","year":"2008","journal-title":"The Lancet"},{"key":"2025090312552001000_5.2.e000993.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101121"},{"key":"2025090312552001000_5.2.e000993.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137703"},{"key":"2025090312552001000_5.2.e000993.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.20568"},{"key":"2025090312552001000_5.2.e000993.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202735"},{"key":"2025090312552001000_5.2.e000993.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209057"},{"key":"2025090312552001000_5.2.e000993.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.24638"},{"key":"2025090312552001000_5.2.e000993.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206106"},{"key":"2025090312552001000_5.2.e000993.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207628"},{"key":"2025090312552001000_5.2.e000993.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"2025090312552001000_5.2.e000993.27","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312552001000_5.2.e000993.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203440"},{"key":"2025090312552001000_5.2.e000993.29","first-page":"25","article-title":"Treatment of recent-onset rheumatoid arthritis: lessons from the best study","volume":"80","author":"Allaart","year":"2007","journal-title":"J Rheumatol Suppl"},{"key":"2025090312552001000_5.2.e000993.30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","article-title":"Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled optima trial","volume":"383","author":"Smolen","year":"2014","journal-title":"The Lancet"},{"key":"2025090312552001000_5.2.e000993.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201612"},{"key":"2025090312552001000_5.2.e000993.32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep261"},{"key":"2025090312552001000_5.2.e000993.33","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000323","article-title":"Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials","volume":"2","author":"Emamikia","year":"2016","journal-title":"RMD Open"},{"key":"2025090312552001000_5.2.e000993.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210708"},{"key":"2025090312552001000_5.2.e000993.35","doi-asserted-by":"crossref","unstructured":"Verschueren P , De Cock D , Corluy L , et al . Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther 2015;17.doi:10.1186\/s13075-015-0611-8","DOI":"10.1186\/s13075-015-0611-8"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-000993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:55:28Z","timestamp":1756929328000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-000993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,7,27]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/rmdopen-2019-000993"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-000993","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}